Newsroom of

Bioanalytical Systems, Inc.

Follow on Social Network
2701 Kent Avenue
West Lafayette, IN 47906
Phone: 800.845.4246
Website: http://BASinc.com

BASi provides drug developers with superior scientific research and innovative analytical instrumentation, which saves time, saves money, and saves lives, to bring revolutionary new drugs to market quickly and safely.

James Bourdage to Retire as BASi VP of Bioanalytical Operations; Michael Baim Named as Successor

Bioanalytical Systems Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that James Bourdage, Ph.D., vice president of Bioanalytical Operations, will retire as of May 4, 2018. Michael Baim, Ph.D., will assume the role of vice president of Bioanalytical Operations effective May 7, 2018.…

BASi and Phlebotics Form Strategic Alliance; Continuing a Commitment to Automated Blood Sampling

BASi and Phlebotics Form Strategic Alliance; Continuing a Commitment to Automated Blood Sampling

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced a technology alliance with Phlebotics, Inc. This agreement is the latest of BASi partnerships, including those with Joanneum Research and PalmSens, to expand their offering of products and services that…

Bolstering Preclinical PK/PD Operations: BASi Hires Karen L. Rogers, DVM, DACLAM, CPIA as Attending Veterinarian

Bolstering Preclinical PK/PD Operations: BASi Hires Karen L. Rogers, DVM, DACLAM, CPIA as Attending Veterinarian

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the addition of Dr. Karen L. Rogers as Attending Veterinarian, Preclinical PK/PD. Dr. Rogers joins recent hires James Burleigh and Candace Rohde Johnson to round out BASi’s expanded team of…

Bioanalytical Systems to Release First Quarter Fiscal 2018 Results on Tuesday, February 13, 2018

Bioanalytical Systems to Release First Quarter Fiscal 2018 Results on Tuesday, February 13, 2018

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced today that it will report financial results for the first quarter of fiscal 2018 ended December 31, 2017, prior to the market opening on Tuesday, February 13, 2018. If there…

BASi Continues Profitability Improvement to Close Out Fiscal 2017

BASi Continues Profitability Improvement to Close Out Fiscal 2017

Bioanalytical Systems, Inc. (NASDAQ:BASI) (" BASi" or the "Company") today announced financial results for the three and twelve months ended September 30, 2017. Fourth Quarter Results For the three months ended September 30, 2017, revenue amounted to $5,873,000, a 14%…

Bioanalytical Systems to Release Fourth Quarter and Full Year Fiscal 2017 Results on Tuesday, December 19, 2017

Bioanalytical Systems to Release Fourth Quarter and Full Year Fiscal 2017 Results on Tuesday, December 19, 2017

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the fourth quarter and twelve months ended September 30, 2017, prior to the market opening on Tuesday, December 19, 2017. If there are…

BASi Announces Enhanced Bioequivalence Capabilities

BASi Announces Enhanced Bioequivalence Capabilities

Bioanalytical Systems Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced a multi-tiered strategy aimed at enhancing the company’s in vitro and in vivo bioequivalence capabilities. Over the next several months, BASi will hire additional Principal Investigators and Research Analysts to support…

Steady Growth Spurs Plans for BASi Expansion of GLP Toxicology Facility in Indiana

Steady Growth Spurs Plans for BASi Expansion of GLP Toxicology Facility in Indiana

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the company has retained architects and consultants to design and complete a multi-phased plan for the expansion of its GLP toxicology facility in Mt. Vernon, Indiana, near Evansville. Steady growth and…

Gaining Momentum: BASi Adds Candace Rohde-Johnson as Director of in Vivo Products and Services

Gaining Momentum: BASi Adds Candace Rohde-Johnson as Director of in Vivo Products and Services

 Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the addition of Candace Rohde-Johnson as Director of In Vivo Products and Services. Ms. Rohde-Johnson will lead BASi’s In Vivo Products and Services Team with a focus on accelerating sales…

BASi Strengthens Preclinical PK/PD Leadership With the Hiring of James E. Burleigh as Director of Operations, Preclinical PK/PD

BASi Strengthens Preclinical PK/PD Leadership With the Hiring of James E. Burleigh as Director of Operations, Preclinical PK/PD

Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company") today announced the addition of James E. Burleigh as Director of Operations, Preclinical PK/PD. "With his vast experience and impeccable reputation, we are incredibly pleased to have Jim Burleigh join the BASi…

BASi and JOANNEUM RESEARCH Enter Into Collaboration to Commercialize Open Flow Microperfusion Technology

BASi and JOANNEUM RESEARCH Enter Into Collaboration to Commercialize Open Flow Microperfusion Technology

Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company"), a recognized global leader in the development of instrumentation for microdialysis and in vivo sampling in animal models, today announced that it has entered into a collaborative agreement with JOANNEUM RESEARCH to commercialize…

BASi Announces New Universal Caging System for Automated Sampling With Focus on Researcher-Friendly Design

BASi Announces New Universal Caging System for Automated Sampling With Focus on Researcher-Friendly Design

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the launch of its Universal Caging System that is compatible with all BASi Culex® Automated In vivo Sampling Systems and BASi Raturn™ Movement Response Systems.   Intended for murine species and guinea pigs, the Universal Cage was designed with a…

Bioanalytical Systems to Release Third Quarter Fiscal 2017 Results on Monday, August 14, 2017

Bioanalytical Systems to Release Third Quarter Fiscal 2017 Results on Monday, August 14, 2017

Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the “Company") announced today that it will report financial results for the third quarter and nine months ended June 30, 2017, prior to the market opening on Monday, Aug. 14, 2017. If there are any…

BASi Announces Election of R. Matthew Neff to the Board of Directors

BASi Announces Election of R. Matthew Neff to the Board of Directors

Bioanalytical Systems, Inc. (NASDAQ: BASI) (“BASi” or the “Company”) today announced that its Board of Directors unanimously elected R. Matthew Neff, as a director, effective August 1, 2017.  "We are pleased to welcome Mr. Neff to the Board and look…

BASi Signs Reseller Agreement With LABEX of MA for Refurbished Culex® Automated Blood Sampling Systems

BASi Signs Reseller Agreement With LABEX of MA for Refurbished Culex® Automated Blood Sampling Systems

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), a recognized global leader in the development of instrumentation for automated blood sampling in animal models, today announced that it has entered into a reseller agreement with LABEX of MA (“LABEX”) for…

BASi Completes Refinancing of Senior Secured Credit Facilities

BASi Completes Refinancing of Senior Secured Credit Facilities

​​​​​​​​​​​​​​​​​​​​Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it has successfully completed the refinancing of its existing senior secured credit facility with a new senior secured credit facility, consisting of a $4.5 million term loan and a…

BASi Names Dr. Gregory C. Davis to Board of Directors

BASi Names Dr. Gregory C. Davis to Board of Directors

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that the board of directors unanimously elected Dr. Gregory C. Davis as a director effective June 14, 2017. This action brings the number of directors to four. Larry Boulet, BASi’s…

BASi Announces Validated 'SEND' Capabilities and Compliance With FDA's Standard for Exchange of Nonclinical Data

BASi Announces Validated 'SEND' Capabilities and Compliance With FDA's Standard for Exchange of Nonclinical Data

 Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced its “SEND” compliance with a fully integrated software solution for streamlining data management and reporting. In partnership with PDS Life Sciences (PDS), BASi has validated TranSEND™, a submission solution that…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login